Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.

Bonon A, Mangolini A, Pinton P, Del Senno L, Aguiari G.

Biochem Biophys Res Commun. 2013 Nov 22;441(3):668-74. doi: 10.1016/j.bbrc.2013.10.076. Epub 2013 Oct 31.

PMID:
24184483
2.

Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.

de Stephanis L, Bonon A, Varani K, Lanza G, Gafà R, Pinton P, Pema M, Somlo S, Boletta A, Aguiari G.

Clin Exp Nephrol. 2017 Apr;21(2):203-211. doi: 10.1007/s10157-016-1289-1. Epub 2016 Jun 9.

PMID:
27278932
3.

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F677-F686. doi: 10.1152/ajprenal.00119.2017. Epub 2017 Jun 14.

PMID:
28615245
4.

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ.

Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23.

PMID:
21345977
5.

Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease.

Yanda MK, Liu Q, Cebotaru V, Guggino WB, Cebotaru L.

J Biol Chem. 2017 Oct 27;292(43):17897-17908. doi: 10.1074/jbc.M117.803775. Epub 2017 Sep 8.

PMID:
28887310
6.

Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.

Seeger-Nukpezah T, Proia DA, Egleston BL, Nikonova AS, Kent T, Cai KQ, Hensley HH, Ying W, Chimmanamada D, Serebriiskii IG, Golemis EA.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12786-91. doi: 10.1073/pnas.1301904110. Epub 2013 Jul 15.

7.

Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice.

Park EY, Sung YH, Yang MH, Noh JY, Park SY, Lee TY, Yook YJ, Yoo KH, Roh KJ, Kim I, Hwang YH, Oh GT, Seong JK, Ahn C, Lee HW, Park JH.

J Biol Chem. 2009 Mar 13;284(11):7214-22. doi: 10.1074/jbc.M805890200. Epub 2008 Dec 20.

8.

Cell Proliferation and Apoptosis in ADPKD.

Lee EJ.

Adv Exp Med Biol. 2016;933:25-34. Review.

PMID:
27730432
9.

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.

Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S.

Hum Mol Genet. 2008 Jun 1;17(11):1505-16. doi: 10.1093/hmg/ddn039. Epub 2008 Feb 7.

10.

Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.

Bastos AP, Onuchic LF.

Braz J Med Biol Res. 2011 Jul;44(7):606-17. Epub 2011 May 27. Review.

11.

Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells.

Aguiari G, Varani K, Bogo M, Mangolini A, Vincenzi F, Durante C, Gessi S, Sacchetto V, Catizone L, Harris P, Rizzuto R, Borea PA, Del Senno L.

Biochim Biophys Acta. 2009 Jun;1792(6):531-40. doi: 10.1016/j.bbadis.2009.03.001. Epub 2009 Mar 11.

12.

c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation.

Elliott J, Zheleznova NN, Wilson PD.

Am J Physiol Cell Physiol. 2011 Aug;301(2):C522-9. doi: 10.1152/ajpcell.00163.2010. Epub 2011 Apr 20.

13.

Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A.

Mol Cell Biol. 2009 May;29(9):2359-71. doi: 10.1128/MCB.01259-08. Epub 2009 Mar 2.

14.

Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.

Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X.

J Clin Invest. 2015 Jun;125(6):2399-412. doi: 10.1172/JCI80467. Epub 2015 May 11.

15.

Mutant polycystin-2 induces proliferation in primary rat tubular epithelial cells in a STAT-1/p21-independent fashion accompanied instead by alterations in expression of p57KIP2 and Cdk2.

Felekkis KN, Koupepidou P, Kastanos E, Witzgall R, Bai CX, Li L, Tsiokas L, Gretz N, Deltas C.

BMC Nephrol. 2008 Aug 25;9:10. doi: 10.1186/1471-2369-9-10.

16.

Multidrug therapy for polycystic kidney disease: a review and perspective.

Aguiari G, Catizone L, Del Senno L.

Am J Nephrol. 2013;37(2):175-82. doi: 10.1159/000346812. Epub 2013 Feb 15. Review.

17.

Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells.

Grimm DH, Karihaloo A, Cai Y, Somlo S, Cantley LG, Caplan MJ.

J Biol Chem. 2006 Jan 6;281(1):137-44. Epub 2005 Nov 8.

18.

Human polycystin-2 transgene dose-dependently rescues ADPKD phenotypes in Pkd2 mutant mice.

Li A, Tian X, Zhang X, Huang S, Ma Y, Wu D, Moeckel G, Somlo S, Wu G.

Am J Pathol. 2015 Oct;185(10):2843-60. doi: 10.1016/j.ajpath.2015.06.014.

19.

Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.

Liu Y, Dai B, Fu L, Jia J, Mei C.

Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):523-30. doi: 10.1111/j.1742-7843.2010.00539.x. Epub 2010 Feb 22.

20.

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M.

Hepatology. 2010 May;51(5):1778-88. doi: 10.1002/hep.23511.

Supplemental Content

Support Center